Literature DB >> 2725573

Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome.

S J Oh1.   

Abstract

Among 13 patients with the Lambert-Eaton myathenic syndrome (LEMS), three different patterns on the repetitive nerve stimulation test were observed at the time of initial testing. Type 1 pattern, seen in one patient, had low normal CMAP amplitude, decremental response at the low rate of stimulation (LRS), and relatively normal response at the high rate of stimulation (HRS). Type 2, seen in nine patients, had the classical triad: low CMAP amplitude, decremental response at LRS, and incremental response at HRS. Type 3, seen in three patients, showed low CMAP amplitude, decremental response at LRS, and initial decremental response at HRS. We believe that these three patterns represent different degrees of blocking in LEMS, from the mildest in type 1 to the most severe in type 3. Since types 1 and 3 can be misinterpreted as myasthenia gravis patterns, they must be recognized in LEMS and an incremental response documented by prolonged stimulation at HRS.

Entities:  

Mesh:

Year:  1989        PMID: 2725573     DOI: 10.1002/mus.880120605

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

1.  Lambert Eaton syndrome: autonomic neuropathy and inappropriate antidiuretic hormone secretion in a patient with small cell carcinoma of the lung.

Authors:  H Manji; M S Schwartz; R O McKeran
Journal:  J Neurol       Date:  1990-08       Impact factor: 4.849

2.  Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.

Authors:  P Maddison; J Newsom-Davis; K R Mills
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

3.  A case of Lambert-Eaton myasthenic syndrome associated with atypical bronchopulmonary carcinoid tumor.

Authors:  Jae-Hyeok Lee; Jin-Hong Shin; Dae-Seong Kim; Dae Soo Jung; Kyu-Hyun Park; Min-Ki Lee; Jee-Yeon Kim
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.